No data pointing to CYP-metabolism. The drug has, however, been shown to interfere with hepatic CYPs in animal studies. Probably of small human clinical significance.

Monocyclic betalactam antibiotic parenterally administered (1-2 g x 3). Used in various gramnegative bacterial infections, e.g. Pneumonia, urinary tract infections, urogenital gonococc infections, upper respiratory tract infections in cystic fibrosis. About 60.-80% ot the dose is excreted in unchanged form in urine within 8 hours. In male rats the total hepatic CYP content is reported to decrease after administration of aztreonam. In female rats the hepatic CYP-activity is slightly increased: Ohmori et al. Aztreonam decreases hepatic … (PMID 8153141). Sagami et al. Effect of aztreonam on immuno... (PMID 2813957). Horie et al. Sex difference in responsiveness... (PMID 3566801)